Last updated on February 2018

Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients


Brief description of study

In this observational study, blood samples for pharmacokinetic (PK) testing will be collected from subjects with metastatic prostate cancer during their treatment with docetaxel. Plasma levels of docetaxel will be determined, and the subjects docetaxel exposure levels, determined as an area under the curve (AUC), will be retrospectively correlated with reports of toxicity, tumor response, quality of life, time to disease progression and overall survival to provide guidance on what the appropriate target range for docetaxel exposure should be for metastatic prostate cancer subjects receiving docetaxel therapy for their disease.

Clinical Study Identifier: NCT02376296

Find a site near you

Start Over

UPMC CancerCenter - Monroeville

Monroeville, PA United States
  Connect »

Arnold Palmer Cancer Center

Greensburg, PA United States
  Connect »

UPMC CancerCenter - Indiana

Indiana, PA United States
  Connect »

UPMC CancerCenter - Horizon

Farrell, PA United States
  Connect »

UPMC CancerCenter - Washington

Washington, PA United States
  Connect »

UPMC CancerCenter - Uniontown

Uniontown, PA United States
  Connect »

UPMC CancerCenter - Mckeesport

McKeesport, PA United States
  Connect »

UPMC CancerCenter - Greenville

Greenville, PA United States
  Connect »

UPMC CancerCenter - New Castle

New Castle, PA United States
  Connect »

UPMC CancerCenter - Jefferson

West Mifflin, PA United States
  Connect »